PVLA: Pieris Pharma Kompaniya qiymatining sof foydaga nisbati
Pieris Pharmaceuticals (PVLA) kompaniyasining harakatlanuvchi P/E ko'rsatkichi aktivning joriy likvidligini namoyish etmoqda, -32.70 esa yangi daraja belgisini qayd etmoqda. Bir nechta klinik sinovlar yakunlanganidan so'ng, biznes hozirda qat'iy restrukturizatsiya va strategik yo'nalishning o'zgarishi jarayonidan o'tmoqda. Pieris Pharmaceuticals (PVLA) inhalatsiya orqali yuboriladigan astma davolash vositalarini ishlab chiqishda Anticalin texnologiyasiga tayanadi. Proprietary savdolarning yo'qligi budjetni tashqi investitsiyalar va shartnomalarga bog'liq qilib qo'ygan.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_PVLA_-_Pieris-Pharmaceuticals_-_PE-Multiple "PVLA: Pieris Pharmaceuticals Biznesning o‘zini qoplash muddati 04.07.2022 - 14.11.2026 | 👁️GURU.Markets👁️")
Pieris Pharmaceuticals Inc (PVLA) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Pieris Pharmaceuticals|PVLA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati Pieris Corp|PVLA - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati Pieris Pharmaceuticals, Inc.|PVLA - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Pieris Pharmaceuticals|Kritik likvidlik koeffitsiyenti pieris.com
- foyda va bozor multiplikatorlari tafsilotlari:
PVLA - Sof foyda|Kompaniya foydasi prognozi Pieris Pharmaceuticals|PVLA - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Pieris Pharma|PVLA - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Pieris Pharmaceuticals, Inc.|PVLA - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Pieris Pharmaceuticals|PVLA - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi pieris.com|PVLA - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Pieris Pharmaceuticals
- realizatsiya hajmi va tushum ko'rsatkichlari:
Kompaniyaning har tomonlama tahlili:pieris.com PVLA
Kapital narx-foyda koeffitsiyentini tahlil qilish orqali barqaror aktivlar va spekulyativ instrumentlarni farqlaydi, bu esa kelajakdagi kutuvlar uchun to'langan premiumni baholash imkonini beradi. Baholanishi antikalinlar uchun o'tkazilayotgan klinik sinovlar natijalariga bog'liq bo'lgan Pieris Pharmaceuticals (PVLA) uchun joriy P/E koeffitsiyenti joriy xarajatlar va kapitalizatsiya salohiyati o'rtasidagi muvozanatning ko'rsatkichi bo'lib xizmat qiladi hamda yuqori noaniqlik sharoitida investitsiyalarning barqarorligini belgilaydi.
Muhim raqobatchilar
P/E multiplikatori argenx.com|Narx-foyda koeffitsiyenti BNTX (BioNTech)|ABVX (ABIVAX) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ADMA (ADMA Bio)|Biznesning o‘zini qoplash muddati Protagonist Corp (PTGX)|IMVT - Narxning foydaga nisbati|kiniksa.com (KNSA) - Narx-foyda koeffitsiyenti|Grifols (GRFS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Adaptive Biotech|Narx-foyda koeffitsiyenti CLDX|P/E multiplikatori Aurinia Corp|Narxning foydaga nisbati BioCryst (BCRX)|veratx.com - Narx-foyda multiplikatori|P/E multiplikatori DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Kapitalizatsiyaning foydaga nisbati|ABCL - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati TRML|PGEN: P/E multiplikatori|PHAR - Biznesning o‘zini qoplash muddati|NKTR (Nektar Therapeutics Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Upstream Bio, Inc. UPB|Narxning foydaga nisbati Zenas Biopharma, Inc. (ZBIO)|IMNM (Immunome Bio) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori GOSS (Gossamer Bio, Inc.)|Biznesning o‘zini qoplash muddati kalvista.com (KALV)|SEPN - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Savara Inc SVRA|RIGL (Rigel Pharmaceuticals Inc) - Narx-foyda koeffitsiyenti|AnaptysBio Inc. - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Astria Therapeutics|engene.com - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori RAPT|JBIO (aerovatetx.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ACRS (Aclaris)|P/E multiplikatori Kyverna Therapeutics, Inc KYTX|TLSA - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati CABA (cabalettabio.com)|Ventyx Biosciences, Inc. (VTYX) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Theratechnologies, Inc.|AVTX (Avalo Therapeutics Inc.) - P/E multiplikatori|P/E multiplikatori Eledon Pharmaceuticals, Inc|P/E multiplikatori AGEN|Narx-foyda koeffitsiyenti climbbio.com CLYM|P/E multiplikatori ZURA (Zura Bio)|aTyr Pharma Inc (ATYR) - Kapitalizatsiyaning foydaga nisbati|ADAG: Narx-foyda koeffitsiyenti|IMA - P/E multiplikatori|STTK (shattucklabs.com) - Narx-foyda koeffitsiyenti|EQ: Bozor narxining sof foydaga nisbati|CNTB (Connect Biopharma Holdings) - P/E multiplikatori|Immunic Inc (IMUX) - Biznesning o‘zini qoplash muddati|P/E multiplikatori ATRA|Narx-foyda koeffitsiyenti inflarx.de IFRX|P/E multiplikatori XFOR (X4 Pharmaceuticals)|P/E multiplikatori Adicet Bio Inc. ACET|CELU - Narxning foydaga nisbati|INMB: Narxning foydaga nisbati|Barinthus Bio (BRNS) - Narxning foydaga nisbati|KZR - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati SAB Biotherapeutics|akaritx.com - Kapitalizatsiyaning sof foydaga nisbati|Narx-foyda koeffitsiyenti ENLV (Enlivex Therapeutics)|Narxning foydaga nisbati QTTB (q32bio.com)|Narxning foydaga nisbati GeoVax Labs Inc GOVX|Edesa Biotech Corp - Narxning foydaga nisbati|iBio, Inc. - P/E multiplikatori|CARM - P/E multiplikatori|XTL Biopharmaceuticals Ltd. (XTLB) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati BOLT (Bolt Biotherapeutics, Inc.)|HCWB (HCW Biologics, Inc.) - P/E multiplikatori|APVO: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AIM|P/E multiplikatori aditxt.com (ADTX)|Narxning foydaga nisbati GRI Bio GRI|Kompaniya qiymatining sof foydaga nisbati XRTX|HIND - Narxning foydaga nisbati|Revelation Biosciences Corp (REVB) - Narx-foyda koeffitsiyenti|INDP: P/E multiplikatori|scinai.com (SCNI) - P/E multiplikatori|Narx-foyda koeffitsiyenti CALI|AFMD: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ALLK|Biznesning o‘zini qoplash muddati hookipapharma.com|Narxning foydaga nisbati IGM Biosciences IGMS|ITOS - Narx-foyda koeffitsiyenti|OCEA - Narxning foydaga nisbati|TC BioPharm (Holdings) Plc (TCBP) - Narx-foyda koeffitsiyenti|THRD (Third Harmonic Bio, Inc) - Narx-foyda koeffitsiyenti
